

Title (en)
TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS

Title (de)
BEHANDLUNG VON HITZEWALLUNGEN, VASOMOTORISCHEN SYMPTOMEN UND NÄCHTLICHEM SCHWITZEN MITTELS SEX-STEROID-VORLÄUFERN IN KOMBINATION MIT SELEKTIVEN ÖSTROGENREZEPTORMODULATOREN

Title (fr)
TRAITEMENT DE BOUFFÉES DE CHALEUR, DE SYMPTÔMES VASOMOTEURS ET DE SUEURS NOCTURNES PAR DES PRÉCURSEURS DE STÉROÏDES SEXUELS EN COMBINAISON AVEC DES MODULATEURS SÉLECTIFS DU RÉCEPTEUR DE L' STROGÈNE

Publication
EP 2442807 A4 20130626 (EN)

Application
EP 10788551 A 20100616

Priority
• CA 2010000898 W 20100616
• US 18754909 P 20090616
• US 79117410 A 20100601

Abstract (en)
[origin: US2010317635A1] Novel methods for reduction or elimination the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes type 2, loss of muscle mass, adiposity, Alzheimer's disease, loss of cognition, loss of memory, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and an antiestrogen or a selective estrogen receptor modulator, particularly compounds having the general structure: Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

IPC 8 full level
A61K 31/453 (2006.01); **A61K 31/085** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/56** (2006.01); **A61K 31/568** (2006.01); **A61K 31/5685** (2006.01); **A61P 15/12** (2006.01)

CPC (source: CN EP KR US)
A61K 9/0034 (2013.01 - KR); **A61K 9/02** (2013.01 - KR); **A61K 9/20** (2013.01 - KR); **A61K 9/48** (2013.01 - KR); **A61K 31/085** (2013.01 - KR); **A61K 31/138** (2013.01 - CN); **A61K 31/192** (2013.01 - CN); **A61K 31/40** (2013.01 - CN); **A61K 31/4025** (2013.01 - CN KR); **A61K 31/4436** (2013.01 - KR); **A61K 31/453** (2013.01 - CN EP KR US); **A61K 31/4535** (2013.01 - CN); **A61K 31/568** (2013.01 - CN EP US); **A61K 31/5685** (2013.01 - CN EP KR US); **A61P 3/00** (2017.12 - EP); **A61P 3/04** (2017.12 - EP); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/24** (2017.12 - EP); **A61P 5/32** (2017.12 - EP); **A61P 5/50** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 15/02** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 15/12** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP)

Citation (search report)
• [Y] MARTEL C ET AL: "Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat.", THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 74, no. 1-2, September 2000 (2000-09-01), pages 45 - 56, XP002695199, ISSN: 0960-0760
• [Y] PICARD F ET AL: "Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats.", INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS : JOURNAL OF THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY, vol. 24, no. 7, July 2000 (2000-07-01), pages 830 - 840, XP002695200, ISSN: 0307-0565
• [Y] LITTLETON-KEARNEY M T ET AL: "SELECTIVE ESTROGEN RECEPTOR MODULATORS: TISSUE ACTIONS AND POTENTIAL FOR CNS PROTECTION", CNS DRUG REVIEWS, vol. 8, no. 3, 2002, BRANFORD, CT, US, pages 309 - 330, XP001145878, ISSN: 1080-563X
• [Y] ELLEDGE ET AL: "1-43 Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer", BREAST DISEASES: A YEAR BOOK QUARTERLY, vol. 16, no. 1, 1 April 2005 (2005-04-01), US, pages 82 - 83, XP005210073, ISSN: 1043-321X, DOI: 10.1016/S1043-321X(05)80067-0
• See references of WO 2010145010A1

Citation (examination)
• DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1990, SWARTZMAN L C ET AL: "Impact of stress on objectively recorded menopausal hot flushes and on flush report bias.", XP002769004, Database accession no. NLM2226383 & SWARTZMAN L C ET AL: "Impact of stress on objectively recorded menopausal hot flushes and on flush report bias.", HEALTH PSYCHOLOGY : OFFICIAL JOURNAL OF THE DIVISION OF HEALTH PSYCHOLOGY, AMERICAN PSYCHOLOGICAL ASSOCIATION 1990, vol. 9, no. 5, 1990, pages 529 - 545, ISSN: 0278-6133
• DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2003 (2003-08-01), YASUI TOSHIYUKI ET AL: "Hormone replacement therapy in postmenopausal women.", XP002769005, Database accession no. PREV200400150656 & YASUI TOSHIYUKI ET AL: "Hormone replacement therapy in postmenopausal women.", JOURNAL OF MEDICAL INVESTIGATION, vol. 50, no. 3-4, August 2003 (2003-08-01), pages 136 - 145, ISSN: 1343-1420

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)
US 2010317635 A1 20101216; AR 077119 A1 20110803; AU 2010262722 A1 20120119; BR PI1011561 A2 20160329; CA 2765446 A1 20101223; CA 2893236 A1 20101223; CL 2011003172 A1 20120525; CN 102458404 A 20120516; CN 104352504 A 20150218; CN 107468695 A 20171215; EA 201200016 A1 20120830; EP 2442807 A1 20120425; EP 2442807 A4 20130626; EP 3178480 A1 20170614; EP 3682880 A1 20200722; HK 1204550 A1 20151127; IL 216963 A0 20120229; IL 216963 A 20171231; IL 248245 A0 20161130; JP 2012530074 A 20121129; JP 2014088442 A 20140515; JP 2016029101 A 20160303; JP 2018203785 A 20181227; KR 20120097470 A 20120904; KR 20140070650 A 20140610; KR 20150141195 A 20151217; KR 20160072269 A 20160622; KR 20170078879 A 20170707; KR 20170138584 A 20171215; KR 20190025752 A 20190311; KR 20190090088 A 20190731; KR 20200108505 A 20200918; KR 20210048609 A 20210503; MA 33434 B1 20120703; MX 2011013689 A 20120402; MX 338290 B 20160407; NZ 597583 A 20141031; SG 10201705761Y A 20170830; SG 10201912379P A 20200227; SG 177497 A1 20120228;

TW 201100403 A 20110101; TW I612044 B 20180121; US 10342805 B2 20190709; US 11452731 B2 20220927; US 2013244989 A1 20130919; US 2019269696 A1 20190905; US 2019269697 A1 20190905; WO 2010145010 A1 20101223; ZA 201109198 B 20120829

DOCDB simple family (application)

US 79117410 A 20100601; AR P100102137 A 20100616; AU 2010262722 A 20100616; BR PI1011561 A 20100616;
CA 2010000898 W 20100616; CA 2765446 A 20100616; CA 2893236 A 20100616; CL 2011003172 A 20111215; CN 201080027160 A 20100616;
CN 201410386309 A 20100616; CN 201710016998 A 20100616; EA 201200016 A 20100616; EP 10788551 A 20100616;
EP 17151727 A 20100616; EP 20158118 A 20100616; HK 15104344 A 20120824; IL 21696311 A 20111213; IL 24824516 A 20161009;
JP 2012515300 A 20100616; JP 2014025183 A 20140213; JP 2015223062 A 20151113; JP 2018189078 A 20181004;
KR 20127001215 A 20100616; KR 20147011740 A 20100616; KR 20157034399 A 20100616; KR 20167015258 A 20100616;
KR 20177017880 A 20100616; KR 20177034988 A 20100616; KR 20197006112 A 20100616; KR 20197021846 A 20100616;
KR 20207026222 A 20100616; KR 20217012518 A 20100616; MA 34540 A 20120116; MX 2011013689 A 20100616; NZ 59758310 A 20100616;
SG 10201705761Y A 20100616; SG 10201912379P A 20100616; SG 2012000410 A 20100616; TW 99119438 A 20100615;
US 201313875027 A 20130501; US 201916418591 A 20190521; US 201916418651 A 20190521; ZA 201109198 A 20111214